Multiple sclerosis (MS) is a chronic neurological disease in which the immune system attacks the protective myelin sheath surrounding nerve fibers in the brain and spinal cord. Over time, this damage disrupts communication between the brain and body, leading to symptoms such as fatigue, weakness, balance problems, muscle stiffness, numbness, and cognitive difficulties. In progressive forms of MS, neurological damage can continue accumulating over time, often resulting in worsening disability and reduced mobility.
Because current therapies primarily focus on managing inflammation rather than repairing damaged nervous system tissue, researchers continue exploring regenerative medicine approaches that may help support neuroprotection and tissue repair. One area receiving growing scientific attention involves mesenchymal stem cell-derived neural progenitors, also known as MSC-NPs.
In this review published in PMC, researchers explored the development of MSC-NP therapy and its potential role in treating progressive multiple sclerosis. The review examined how these specialized cells are created, how they may function within the nervous system, and what early clinical research has shown so far.
What Are MSC-Derived Neural Progenitors?
Mesenchymal stem cells (MSCs) are regenerative cells that can be obtained from tissues such as bone marrow and umbilical cord tissue. Researchers have studied MSCs extensively because of their anti-inflammatory, immunomodulatory, and regenerative properties.
According to the review, MSC-derived neural progenitors are specialized cells developed from mesenchymal stem cells under controlled laboratory conditions. During this process, MSCs are exposed to growth factors and signaling environments that encourage them to develop neural-supportive characteristics. Researchers believe these neural progenitor-like cells may provide enhanced support for nervous system repair compared to traditional MSCs alone.
The authors explained that MSC-NPs may help create a more supportive environment within damaged nervous tissue by releasing signaling molecules involved in:
- Immune regulation
- Neuroprotection
- Tissue repair
- Neuronal survival
- Inflammation control
These properties have made MSC-NPs an important focus in progressive MS research.
How MSC-NPs May Support the Nervous System
One of the major themes discussed in the review involves the ability of MSC-NPs to influence multiple biological pathways associated with MS progression. Researchers noted that these cells appear capable of interacting with inflammatory immune activity while simultaneously supporting repair-related processes within the central nervous system.
The review described how MSC-NPs release trophic factors, cytokines, and extracellular signaling molecules that may help protect neurons and support communication between cells involved in tissue repair. Researchers also highlighted evidence suggesting MSC-NPs may help reduce inflammatory damage within the nervous system while promoting a more regenerative cellular environment.
Unlike therapies designed to target a single inflammatory pathway, MSC-NPs appear capable of influencing several mechanisms simultaneously, which researchers believe may be particularly valuable in complex neurological diseases like MS.
Early Clinical Research in Progressive MS
The review also summarized early clinical studies investigating MSC-NP therapy in patients with progressive forms of multiple sclerosis. Researchers reported encouraging findings involving safety, tolerability, and potential neurological benefits following treatment.
According to the review, several patients participating in early-phase clinical trials experienced stabilization or improvement in neurological function following MSC-NP therapy. Researchers observed improvements in measures involving mobility, muscle strength, and disability scores in certain participants.
The review additionally highlighted long-term follow-up findings suggesting that some patients maintained clinical improvements for extended periods after treatment. Researchers believe these outcomes support continued investigation into MSC-NP therapy as a regenerative medicine approach for progressive MS.
Importantly, MSC-NP therapy was also reported to demonstrate a favorable safety profile in early clinical studies, further supporting ongoing research in this area.
A Growing Area of Regenerative Medicine Research
This review highlights the growing scientific interest surrounding mesenchymal stem cell-derived neural progenitors and their potential role in supporting patients with progressive multiple sclerosis. Researchers continue exploring how these specialized cells may help regulate inflammation, protect nervous tissue, and support repair-related processes within the central nervous system.
Although larger clinical trials are still needed, MSC-NPs continue to demonstrate encouraging potential in regenerative medicine research. As scientists gain a better understanding of how these cells interact with the immune system and nervous system, MSC-NP therapy may become an increasingly important area of study in the future of neurological disease research and supportive care.
Source
Ghareghani M, Reiter CR, Sadiq SA. The evolution of mesenchymal stem cell-derived neural progenitors (MSC-NPs) in multiple sclerosis. Front Cell Neurosci. 2024;18:1428652. doi: 10.3389/fncel.2024.1428652. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11393827/